Brief: Atossa Therapeutics Inc Receives Authorization From FDA

Atossa Therapeutics

24/10/2022 14:24

Oct 24 (Reuters) - Atossa Therapeutics Inc  ATOS.O :
    * ATOSSA THERAPEUTICS, INC. RECEIVES AUTHORIZATION FROM FDA
TO
INITIATE ITS PHASE 2 STUDY OF NEOADJUVANT (Z)-ENDOXIFEN IN
PREMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER
    * ATOSSA THERAPEUTICS- IT IS DISCONTINUING ITS COVID-19
PROGRAM
(AT-301) SO THAT IT CAN REFOCUS RESOURCES ON THIS CRITICAL STUDY
IN BREAST CANCER
    * ATOSSA THERAPEUTICS -  FDA HAS LIFTED CLINICAL HOLD AND
AUTHORIZED INITIATION OF ITS PHASE 2 NEOADJUVANT CLINICAL STUDY
OF (Z)-ENDOXIFEN

Source text for Eikon:  ID:nGNX68KrwG 
Further company coverage:  ATOS.O 
 ((Reuters.Briefs@thomsonreuters.com;))